There are three main classifications of cell therapies: advanced therapy medicinal products (ATMPs), ATMPs prepared on a non-routine basis (hospital exemptions), and minimally manipulated cells. Cell therapies are subject to complex pathways to reach the market in France, despite the benefits that they can bring to patients. This study aimed to investigate the variations in market access routes for cell therapies in France based on their regulatory status, and describe them accordingly.
